Pair recommendations for SARS-CoV-2 antibodies in lateral flow

5 Jan, 2021


no comments

Now available: monoclonal antibodies specific to SARS-CoV-2 nucleoprotein in lateral flow.

Four anti-SARS-CoV-2 nucleoprotein antibodies are now available from Advanced ImmunoChemical in their final forms: in vivo C518, C525, C706 and C715. In addition, one of our anti-Spike clones, RBD1107, is now available as an in vitro product R107. The antibodies have been tested with COVID-19 positive patient samples.

The best pairs in lateral flow are shown below: three capture-detection pairs: C715-C706, C706-NP1524 and C706-C518 that can detect the antigen with a 1:20,000 dilution of virus lysate.

Figure 1. Detection of SARS-CoV-2 nucleoprotein in lateral flow. Antigen: SARS-CoV-2 lysate, titer 1.15 x 107 TCID 50/mL

For a list of these antibodies and pair recommendations, see data sheet below:

Cat. #5-CVnp. Monoclonal Anti-SARS-CoV-2, nucleoprotein

COVID-19 related monoclonal antibodies are now available, nine antibodies specific to SARS-CoV-2 nucleoprotein and three antibodies specific to Spike (RBD). Please note that antibodies are produced as in vivo products. The same antibodies are also available in recombinant or in vitro formats.

Cat. #5-CVs. Monoclonal Anti-SARS-CoV-2, spike

SARS-CoV-2 is a novel coronavirus causing COVID-19. In March 2020, the World Health Organization announced the COVID-19 outbreak as a pandemic. SARS-CoV-2 belongs to a large family of single-stranded RNA viruses (+ssRNA). Beta-coronaviruses such as SARS-CoVs can cross species barriers and cause in humans illness ranging from a common cold to more severe diseases such as Severe Acute Respiratory Syndorme (SARS, identified in 2003) and Middle East Respiratory Syndrome (MERS, identified in 2012).

Browse our full product line:

Advanced ImmunoChemical is open and business continues as normal. We confirm that we are continuing to supply our products as normal and do not foresee any significant disruption in product availability or ship schedules. Please know we will continue to follow developments and do our best to advise you as soon as possible if the situation changes.

Skip to toolbar